NEW YORK, NY
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)SAMUEL WAXMAN CANCER RESEARCH FOUNDATION, founded in 1980, is a community nonprofit that reported $2.2M in total revenue in fiscal year 2024. Revenue fell 23% from the prior year — a significant decline worth monitoring. Expenses of $2.8M exceeded revenue, resulting in a 27% operating deficit.
THE SAMUEL WAXMAN CANCER RESEARCH FOUNDATION (THE "FOUNDATION") FUNDS INNOVATIVE RESEARCH TO BRING FASTER CURES TO PATIENTS. IN ADDITION TO SUPPORTING ONGOING COLLABORATIVE RESEARCH IN SPECIFIC CANCERS, OUR SCIENTISTS ARE INVESTIGATING THE BIOLOGY OF CANCER TO FIND TREATMENTS ACROSS THE DISEASE.
THE SAMUEL WAXMAN CANCER RESEARCH FOUNDATION IS AN INTERNATIONAL ORGANIZATION DEDICATED TO CURING AND PREVENTING CANCER. THE FOUNDATION IS A PIONEER IN CANCER RESEARCH FOCUSING ON UNCOVERING THE...
THE SAMUEL WAXMAN CANCER RESEARCH FOUNDATION IS AN INTERNATIONAL ORGANIZATION DEDICATED TO CURING AND PREVENTING CANCER. THE FOUNDATION IS A PIONEER IN CANCER RESEARCH FOCUSING ON UNCOVERING THE CAUSES OF CANCER AND REPROGRAMMING CANCER CELLS. WE DEDICATE OURSELVES TO DELIVERING TAILORED, MINIMALLY TOXIC TREATMENTS TO PATIENTS. OUR MISSION IS TO ERADICATE CANCER BY BRIDGING THE GAP BETWEEN LAB SCIENCE AND THE PATIENT. THROUGH OUR COLLABORATIVE GROUP OF WORLD-CLASS SCIENTISTS, THE INSTITUTE WITHOUT WALLS, INVESTIGATORS SHARE INFORMATION AND TOOLS TO SPEED THE PACE OF CANCER RESEARCH. SINCE OUR INCEPTION IN 1976, THE FOUNDATION HAS AWARDED MORE THAN $120 MILLION TO SUPPORT THE WORK OF MORE THAN 200 RESEARCHERS ACROSS THE GLOBE.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $2,210,348 | $2,861,160 | -0.2% |
| Expenses | $2,806,670 | $3,737,329 | -0.2% |
| Net Income | $-596,322 | $-876,169 | -0.3% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| DENA K WEINER | VICE-PRESIDENT | 2.0 |
Officer
Director
|
$0 | $0 | $0 |
| GERARD J JOYCE | SECRETARY | 2.0 |
Officer
Director
|
$0 | $0 | $0 |
| MICHAEL NIERENBERG | CHAIRMAN | 2.0 |
Officer
Director
|
$0 | $0 | $0 |
| NICK SANTORO | TREASURER (as of 07/01/2024) | 2.0 |
Officer
Director
|
$0 | $0 | $0 |
| SAMUEL WAXMAN MD | DIRECTOR-CEO | 20.0 |
Officer
Director
|
$250,000 | $0 | $250,000 |
| SPENCER WAXMAN | PRESIDENT | 2.0 |
Officer
Director
|
$0 | $0 | $0 |
| ARI ZAGDANSKI | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| BARON SILVERSTEIN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| CHRISITNE ARLOTTA | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| DENNIS A HERMAN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| ETHAN DMITROVSKY MD | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| FREDRICK W BARNEY | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| GARY JACOB | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| GARY NOLAN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| HOWAD SHLAFMITZ | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| JAMES FRANKEL | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| JAMES A INGRAM | DIRECTOR (THRU 02/01/2025) | 1.0 |
Director
|
$0 | $0 | $0 |
| JOSEPH STEFFA | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| KENNETH FISHEL | DIRECTOR (THRU 05/01/2025) | 1.0 |
Director
|
$0 | $0 | $0 |
| LEWIS A RUBIN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| LINDA HERMAN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| MARC TAUB | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| PEEYUSH MISRA | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| RIVA ARIELLA RITVO-SLIFKA | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| SCOTT WAXMAN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| SUSEAN PERNICK | DIRECTOR (AS OF 03/01/2025) | 1.0 |
Director
|
$0 | $0 | $0 |
| W DAVID HINKELMAN | DIRECTOR | 1.0 |
Director
|
$0 | $0 | $0 |
| GREGORY FABIJANCZUK | CFO/DIRECTOR OF FINANCE (thru 04/30/2025) | 40.0 |
Officer
|
$145,613 | $42,597 | $188,210 |
| WILLIAM T SULLIVAN | EXECUTIVE DIRECTOR | 50.0 |
Key Emp
|
$342,514 | $88,934 | $431,448 |
| KAREN KIRK | DIRECTOR OF SPECIAL EVENTS | 40.0 |
Highest
|
$121,650 | $72,628 | $194,278 |
| Suzanna C Houston | Director of Special Projects | 40.0 |
Highest
|
$130,750 | $30,999 | $161,749 |
| WYLIE TENE | DIRECTOR OF MARKETING & COMMUNICATION | 40.0 |
Highest
|
$140,472 | $31,981 | $172,453 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $2,210,348 | $2,806,670 | $4,595,379 | $-596,322 |
| 2024 | $2,861,160 | $3,737,329 | $5,376,278 | $-876,169 |
| 2023 | $4,008,774 | $4,004,625 | $6,175,563 | $4,149 |
| 2022 | $4,706,095 | $2,897,746 | $6,125,031 | $1,808,349 |
| 2021 | $2,510,809 | $3,593,053 | $4,834,675 | $-1,082,244 |
| 2020 | $5,207,449 | $3,385,729 | $5,139,332 | $1,821,720 |
| 2019 | $4,078,871 | $2,935,725 | $3,328,184 | $1,143,146 |
| 2018 | $3,647,263 | $2,779,634 | $2,187,127 | $867,629 |
Compare SAMUEL WAXMAN CANCER RESEARCH FOUNDATION with other nonprofits in New York and across the country.